Blocking antibodies of Notch receptors: (i) OMP-52M51 (also called brontictuzumab), an anti-Notch1 monoclonal antibody (mAb), was tested in the clinic to treat lymphoid malignancies [29], solid tumor [30], adenoid cystic carcinoma (ACC) [31], and metastatic CRC. This evidence concerns the gene NOTCH1 and adrenal cortex carcinoma.